Genomic Characterization And Experimental Modeling Of Bcr-Abl1-Like Acute Lymphoblastic Leukemia

Yongjin Li,Debbie Payne-Turner,Richard C. Harvey,Jinjun Cheng,Jinghui Zhang,Guangchun Song,Yung-Li Yang,Natalia Santiago-Morales,Deqing Pei,Cheng Cheng,Jing Ma,Shann-Ching Chen,Michael Rusch,Pankaj Gupta,Meenakshi Devidas,I-Ming Chen,Eric Larsen,Naomi J. Winick,William L. Carroll,Nyla A. Heerema,Andrew J. Carroll,Julie M. Gastier-Foster,Elizabeth A. Raetz,Ching-Hon Pui,Sima Jeha,James R. Downing,Elisabeth Paietta,Steven M. Kornblau,Guido Marcucci,Clara D. Bloomfield,Daniela S. Gerhard,Mignon L. Loh,Cheryl L. Willman,Stephen P. Hunger,Charles G. Mullighan

DOI: https://doi.org/10.1182/blood.V122.21.232.232

IF: 20.3

2013-01-01

Blood

Abstract:BCR-ABL1-like B-progenitor acute lymphoblastic leukemia (B-ALL) accounts for 10-15% of childhood B-ALL and is characterized by alteration of IKZFI, a gene expression profile similar to BCR-ABL1 ALL and poor outcome. Using next-generation sequencing, we have shown that BCR-ABL1-like ALL patients harbor genetic alterations activating kinase pathways that are sensitive to tyrosine kinase inhibitors (TKIs), and have shown that refractory BCR-ABL1-like ALL is responsive to TKIs in vivo (Weston et al., J. Clin. Oncol 2013). Furthermore, the outcome of ALL in adolescent and young adult (AYA) patients is inferior to children, yet the genetic basis underlying treatment failure is poorly understood.